{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-207749","form_type":"8-K","ticker":null,"cik":"0001538210","company_name":"NexImmune, Inc.","filed_at":"2024-08-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.446309+00:00","generated_at":"2026-05-31T07:23:21.429410+00:00","sec_items":["5.02","8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"NexImmune appoints wind-down officer; all directors and execs resign after shareholder-approved dissolution","bullets":["All eight directors, including CEO Kristi Jones, CSO Mathias Oelke, and interim CFO Albert Marchio, resigned effective Aug 27, 2024.","Craig Jalbert appointed as sole director, President, Treasurer, Corporate Secretary, and principal executive/financial officer effective Aug 27.","Jalbert to receive $50,000/year for three years for winding down the company.","Board approved filing certificate of dissolution with Delaware Secretary of State upon completion of wind-down.","Company cautions trading in NEXI stock is highly speculative; urges extreme caution."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-207749","json":"https://secwatch.observer/filing/0001193125-24-207749.json","markdown":"https://secwatch.observer/filing/0001193125-24-207749.md","text":"https://secwatch.observer/filing/0001193125-24-207749.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1538210/000119312524207749/0001193125-24-207749-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1538210/000119312524207749/d890897d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T07:23:21.429410+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"04c6c25347","claim":"Kristi Jones resigned as Director at NexImmune, Inc..","evidence_excerpt":"On August 21, 2024, Sol J. Barer, Kristi Jones, Alan S. Roemer, Tim Bertram, Paul D’Angio, Grant Verstandig, Zhengbin (Bing) Yao and Leena Gandhi, each notified the Company of their respective resignations as members of the Company’s Board of Directors (the “Board”), effective as of August 27, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1538210/000119312524207749/0001193125-24-207749-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"0eb7e7b120","claim":"Craig Jalbert was appointed as President at NexImmune, Inc..","evidence_excerpt":"the Board also appointed Craig Jalbert, age 63, as the Company’s President, Treasurer and Corporate Secretary and as the Company’s principal executive officer, principal financial officer and principal accounting officer, effective as of August 27, 2024, and as the sole member of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1538210/000119312524207749/0001193125-24-207749-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"20cbd4ade6","claim":"Kristi Jones resigned as Chief Executive Officer at NexImmune, Inc..","evidence_excerpt":"The resignations of Kristi Jones, the Company’s Chief Executive Officer, Mathias Oelke, the Company’s Chief Scientific Officer, and Albert N. Marchio II, the Company’s Interim Chief Financial Officer and its principal financial and accounting officer from the Company were not due to any disagreements with the Company on any matters relating to the Company’s operations, policies or practices.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1538210/000119312524207749/0001193125-24-207749-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"2d7dbd71a1","claim":"Leena Gandhi resigned as Director at NexImmune, Inc..","evidence_excerpt":"On August 21, 2024, Sol J. Barer, Kristi Jones, Alan S. Roemer, Tim Bertram, Paul D’Angio, Grant Verstandig, Zhengbin (Bing) Yao and Leena Gandhi, each notified the Company of their respective resignations as members of the Company’s Board of Directors (the “Board”), effective as of August 27, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1538210/000119312524207749/0001193125-24-207749-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"4de0730462","claim":"Sol J. Barer resigned as Director at NexImmune, Inc..","evidence_excerpt":"On August 21, 2024, Sol J. Barer, Kristi Jones, Alan S. Roemer, Tim Bertram, Paul D’Angio, Grant Verstandig, Zhengbin (Bing) Yao and Leena Gandhi, each notified the Company of their respective resignations as members of the Company’s Board of Directors (the “Board”), effective as of August 27, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1538210/000119312524207749/0001193125-24-207749-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"59149316ab","claim":"Alan S. Roemer resigned as Director at NexImmune, Inc..","evidence_excerpt":"On August 21, 2024, Sol J. Barer, Kristi Jones, Alan S. Roemer, Tim Bertram, Paul D’Angio, Grant Verstandig, Zhengbin (Bing) Yao and Leena Gandhi, each notified the Company of their respective resignations as members of the Company’s Board of Directors (the “Board”), effective as of August 27, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1538210/000119312524207749/0001193125-24-207749-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"6a24c6b572","claim":"Grant Verstandig resigned as Director at NexImmune, Inc..","evidence_excerpt":"On August 21, 2024, Sol J. Barer, Kristi Jones, Alan S. Roemer, Tim Bertram, Paul D’Angio, Grant Verstandig, Zhengbin (Bing) Yao and Leena Gandhi, each notified the Company of their respective resignations as members of the Company’s Board of Directors (the “Board”), effective as of August 27, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1538210/000119312524207749/0001193125-24-207749-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"7d1319f6f9","claim":"Zhengbin (Bing) Yao resigned as Director at NexImmune, Inc..","evidence_excerpt":"On August 21, 2024, Sol J. Barer, Kristi Jones, Alan S. Roemer, Tim Bertram, Paul D’Angio, Grant Verstandig, Zhengbin (Bing) Yao and Leena Gandhi, each notified the Company of their respective resignations as members of the Company’s Board of Directors (the “Board”), effective as of August 27, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1538210/000119312524207749/0001193125-24-207749-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"8b5679ee94","claim":"Tim Bertram resigned as Director at NexImmune, Inc..","evidence_excerpt":"On August 21, 2024, Sol J. Barer, Kristi Jones, Alan S. Roemer, Tim Bertram, Paul D’Angio, Grant Verstandig, Zhengbin (Bing) Yao and Leena Gandhi, each notified the Company of their respective resignations as members of the Company’s Board of Directors (the “Board”), effective as of August 27, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1538210/000119312524207749/0001193125-24-207749-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"8f0c6e31c3","claim":"Albert N. Marchio II resigned as Interim Chief Financial Officer at NexImmune, Inc..","evidence_excerpt":"The resignations of Kristi Jones, the Company’s Chief Executive Officer, Mathias Oelke, the Company’s Chief Scientific Officer, and Albert N. Marchio II, the Company’s Interim Chief Financial Officer and its principal financial and accounting officer from the Company were not due to any disagreements with the Company on any matters relating to the Company’s operations, policies or practices.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1538210/000119312524207749/0001193125-24-207749-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Interim Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"b7ae7cacdb","claim":"Mathias Oelke resigned as Chief Scientific Officer at NexImmune, Inc..","evidence_excerpt":"The resignations of Kristi Jones, the Company’s Chief Executive Officer, Mathias Oelke, the Company’s Chief Scientific Officer, and Albert N. Marchio II, the Company’s Interim Chief Financial Officer and its principal financial and accounting officer from the Company were not due to any disagreements with the Company on any matters relating to the Company’s operations, policies or practices.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1538210/000119312524207749/0001193125-24-207749-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"},{"claim_id":"f5a5b93c8b","claim":"Paul D'Angio resigned as Director at NexImmune, Inc..","evidence_excerpt":"On August 21, 2024, Sol J. Barer, Kristi Jones, Alan S. Roemer, Tim Bertram, Paul D’Angio, Grant Verstandig, Zhengbin (Bing) Yao and Leena Gandhi, each notified the Company of their respective resignations as members of the Company’s Board of Directors (the “Board”), effective as of August 27, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1538210/000119312524207749/0001193125-24-207749-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}